Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-B4822M in Relapsed/Refractory Multiple Myeloma
NCT03674463Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of LCAR-B4822M in multiple myeloma (MM), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Adverse Events at 30 days. Status: unknown.
02
Drugs
LCAR-B4822M
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03674463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674463.